^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Radspherin

    Associations

    News

    Trials
    Company:
    Oncoinvent
    Drug class:
    Ionizing radiation emitter
    Related drugs:
    Associations

    News

    Trials
    3ms
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1/2, N=47, Completed, Oncoinvent AS | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Radspherin
    over1year
    A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (clinicaltrials.gov)
    P2, N=114, Recruiting, Oncoinvent AS
    New P2 trial • Surgery • Metastases
    |
    Radspherin
    over1year
    Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1/2, N=67, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Radspherin
    over1year
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=49, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Radspherin
    over2years
    Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy. (PubMed, Technol Cancer Res Treat)
    Our study showed a predominately local rather than systemic inflammatory response to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Radspherin® had overall modest impact on the inflammation.
    Journal • Surgery
    |
    IFNG (Interferon, gamma) • CCL4 (Chemokine (C-C motif) ligand 4) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Radspherin